Plain-English translation of NCT04519905 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether elderly patients with esophageal squamous cell carcinoma benefit from receiving paclitaxel and carboplatin (two chemotherapy drugs) alongside radiation therapy, rather than radiation therapy alone. Researchers want to know if this combination approach helps people live longer and have a better quality of life.
Until now, older patients with this type of esophageal cancer have primarily received radiation therapy by itself. This trial exists to answer an important question: can eligible elderly patients actually live longer and feel better if they receive the new treatment in combination with radiation?
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to one of two groups: either radiation therapy combined with weekly chemotherapy infusions (paclitaxel and carboplatin) for five weeks, or radiation therapy alone at a higher dose. Throughout treatment, you would visit the clinic regularly for treatment sessions, blood tests, and check-ups. Researchers will monitor your health, track any side effects, and ask you to complete questionnaires about your quality of life and any symptoms you experience. Follow-up care would continue for at least 3 years to measure how well the treatment worked.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China